Alterations in the serotonin system in schizophrenia: a systematic review and meta-analysis of postmortem and molecular imaging studies.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Neuroscience and Biobehavioral Reviews

• Publication date

  2014-09-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1016/j.neubiorev.2014.06.005PMID 24971825
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Characterization of [11C]Cimbi-36 as an agonist PET radioligand for the 5-HT2A and 5-HT2C receptors in the nonhuman primate brain

  2014cited by this paper
• Facial and Prosodic Emotion Recognition Deficits Associate with Specific Clusters of Psychotic Symptoms in Schizophrenia

  2013cited by this paper
• Emotion regulation abnormalities in schizophrenia: cognitive change strategies fail to decrease the neural response to unpleasant stimuli.

  2013cited by this paper
• Dysregulated 5-HT(2A) receptor binding in postmortem frontal cortex of schizophrenic subjects.

  2013cited by this paper
• Presynaptic striatal dopamine dysfunction in people at ultra-high risk for psychosis: findings in a second cohort.

  2013cited by this paper
• Effect of a single dose of escitalopram on serotonin concentration in the non-human and human primate brain.

  2013cited by this paper
• Serotonin 5-HT1A Receptors as Targets for Agents to Treat Psychiatric Disorders: Rationale and Current Status of Research

  2013cited by this paper
• Magnetic resonance imaging studies in unipolar depression: systematic review and meta-regression analyses.

  2012cited by this paper
• RETRACTED: Dysregulated glutamate and dopamine transporters in postmortem frontal cortex from bipolar and schizophrenic patients.

  2012cited by this paper
• Neuroanatomy of Serotonergic Abnormalities in Suicide

  2012cited by this paper
• Measuring endogenous changes in serotonergic neurotransmission in humans: a [11C]CUMI-101 PET challenge study

  2012cited by this paper
• The relationship between antipsychotic D2 occupancy and change in frontal metabolism and working memory

  2012cited by this paper
• Twenty-five years of glutamate in schizophrenia: are we there yet?

  2012cited by this paper
• Serotonergic mechanisms as targets for existing and novel antipsychotics.

  2012cited by this paper
• NMDA receptor and schizophrenia: a brief history.

  2012cited by this paper
• The nature of dopamine dysfunction in schizophrenia and what this means for treatment.

  2012cited by this paper
• Conducting quantitative synthesis when comparing medical interventions: AHRQ and the Effective Health Care Program.

  2011cited by this paper
• Progressive increase in striatal dopamine synthesis capacity as patients develop psychosis: a PET study

  2011cited by this paper
• Behavioral / Systems / Cognitive Serotonin-1 A Autoreceptors Are Necessary and Sufficient for the Normal Formation of Circuits Underlying Innate Anxiety

  2011cited by this paper
• Hippocampal dysregulation of dopamine system function and the pathophysiology of schizophrenia.

  2011cited by this paper
• Decreased frontal serotonin2A receptor binding in antipsychotic-naive patients with first-episode schizophrenia.

  2010cited by this paper
• Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysis.

  2010cited by this paper
• Altered relationship between hippocampal glutamate levels and striatal dopamine function in subjects at ultra high risk of psychosis.

  2010cited by this paper
• Decreased density of serotonin 2A receptors in the superior temporal gyrus in schizophrenia--a postmortem study.

  2009cited by this paper
• Effects of HTR1A C(-1019)G on amygdala reactivity and trait anxiety.

  2009cited by this paper
• Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo

  2009cited by this paper
• Magnetic resonance imaging studies in bipolar disorder and schizophrenia: meta-analysis.

  2009cited by this paper
• Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging.

  2009cited by this paper
• The dopamine hypothesis of schizophrenia: version III--the final common pathway.

  2009cited by this paper
• Psychiatric comorbidities and schizophrenia.

  2009cited by this paper
• Elevated striatal dopamine function linked to prodromal signs of schizophrenia.

  2009cited by this paper
• Is facial emotion recognition impairment in schizophrenia identical for different emotions? A signal detection analysis.

  2008cited by this paper
• Serotonin research: contributions to understanding psychoses.

  2008cited by this paper
• Identification of a serotonin/glutamate receptor complex implicated in psychosis

  2008cited by this paper
• Serotonin 5-HT1A receptor binding in people with panic disorder: positron emission tomography study.

  2008cited by this paper
• Evidence for altered post-receptor modulation of the serotonin 2a receptor in schizophrenia.

  2008cited by this paper
• Impaired emotion perception in schizophrenia: a differential deficit.

  2007cited by this paper
• Can antidepressants prevent psychosis?

  2007cited by this paper
• Serotonin, Inhibition, and Negative Mood

  2007cited by this paper
• 5-HT2A receptor density is decreased in the at-risk mental state

  2007cited by this paper
• Alterations of serotonin transmission in schizophrenia.

  2007cited by this paper
• Serotonin 1a receptor and associated G-protein activation in schizophrenia and bipolar disorder.

  2006cited by this paper
• Essential Role of BDNF in the Mesolimbic Dopamine Pathway in Social Defeat Stress

  2006cited by this paper
• Impairment in the specificity of emotion processing in schizophrenia.

  2006cited by this paper
• Cortical serotonin7, 1D and 1F receptors: effects of schizophrenia, suicide and antipsychotic drug treatment.

  2006cited by this paper
• Serotonin 1A receptor availability in patients with schizophrenia and schizo-affective disorder: a positron emission tomography imaging study with [11C]WAY 100635

  2006cited by this paper
• Cortical 5-HT2A Receptor Signaling Modulates Anxiety-Like Behaviors in Mice

  2006cited by this paper
• Neuropharmacology of 5-hydroxytryptamine.

  2006cited by this paper
• Altered serotonin 1A binding in major depression: a [carbonyl-C-11]WAY100635 positron emission tomography study.

  2006cited by this paper
• Mapping the Onset of Psychosis: The Comprehensive Assessment of At-Risk Mental States

  2005cited by this paper
• Changes in the serotonin transporter in the hippocampus of subjects with schizophrenia identified using [3H]paroxetine

  2005cited by this paper
• Serotonin transporter availability in patients with schizophrenia: a positron emission tomography imaging study with [11C]DASB.

  2005cited by this paper
• 5-HT2A and muscarinic receptors in schizophrenia: a postmortem study.

  2005cited by this paper
• Binding characteristics of the 5‐HT2A receptor antagonists altanserin and MDL 100907

  2005cited by this paper
• Quantification of 11C-MADAM binding to the serotonin transporter in the human brain.

  2005cited by this paper
• Consensus Statement

  2004cited by this paper
• Expression of serotonin1A and serotonin2A receptors in pyramidal and GABAergic neurons of the rat prefrontal cortex.

  2004cited by this paper
• The GABA-glutamate connection in schizophrenia: which is the proximate cause?

  2004cited by this paper
• Decreased 5-HT1A receptor binding in amygdala of schizophrenia.

  2004cited by this paper
• Serotonin1A receptors at the axon initial segment of prefrontal pyramidal neurons in schizophrenia.

  2004cited by this paper
• Hippocampal 5-hydroxytryptamine receptors: abnormalities in postmortem brain from schizophrenic subjects.

  2004cited by this paper
• A Positron Emission Tomography Study of the 5-Ht1A Receptor in Schizophrenia and during Clozapine Treatment

  2004cited by this paper
• The cortical serotonin2A receptor and the pathology of schizophrenia: a likely accomplice

  2003cited by this paper
• Measuring inconsistency in meta-analyses

  2003cited by this paper
• Regulation by 5-HT1A receptors of the in vivo release of 5-HT and DA in mouse frontal cortex.

  2003cited by this paper
• Abnormal behavioral phenotypes of serotonin transporter knockout mice: parallels with human anxiety and depression.

  2003cited by this paper
• Involvement of serotonin in depression: evidence from postmortem and imaging studies of serotonin receptors and the serotonin transporter.

  2003cited by this paper
• Serotonin1A receptor acts during development to establish normal anxiety-like behaviour in the adult

  2002cited by this paper
• Comparative Evaluation in Nonhuman Primates of Five PET Radiotracers for Imaging the Serotonin Transporters: [11C]McN 5652, [11C]ADAM, [11C]DASB, [11C]DAPA, and [11C]AFM

  2002cited by this paper
• Ritanserin antagonism of m-chlorophenylpiperazine effects in neuroleptic-free schizophrenics patients: support for serotonin-2 receptor modulation of schizophrenia symptoms

  2002cited by this paper
• Serotonin Transporter Genetic Variation and the Response of the Human Amygdala

  2002cited by this paper
• Brain serotonin 5-HT(1A) receptor binding in schizophrenia measured by positron emission tomography and [11C]WAY-100635.

  2002cited by this paper
• [3H]-SB-269970 radiolabels 5-HT7 receptors in rodent, pig and primate brain tissues.

  2002cited by this paper
• Long-term effects of olanzapine, risperidone, and quetiapine on serotonin 1A, 2A and 2C receptors in rat forebrain regions

  2002cited by this paper
• Expression of serotonin 5‐HT2A receptors in the human cerebellum and alterations in schizophrenia

  2001cited by this paper
• 5‐HT2A and D2 receptor blockade increases cortical DA release via 5‐HT1A receptor activation: a possible mechanism of atypical antipsychotic‐induced cortical dopamine release

  2001cited by this paper
• Serotonin model of schizophrenia: emerging role of glutamate mechanisms.

  2000cited by this paper
• Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group.

  2000cited by this paper
• Dopamine and serotonin transporters in patients with schizophrenia: an imaging study with [123I]β-CIT

  2000cited by this paper
• Serotonin(2A) receptors are reduced in the planum temporale from subjects with schizophrenia.

  2000cited by this paper
• Serotonin 5-HT2 receptors in schizophrenic patients studied by positron emission tomography.

  2000cited by this paper
• Brain serotonin1A receptor binding measured by positron emission tomography with [11C]WAY-100635: effects of depression and antidepressant treatment.

  2000cited by this paper
• Decreased serotonin 2A receptor densities in neuroleptic-naive patients with schizophrenia: A PET study using [(18)F]setoperone.

  2000cited by this paper
• Dopamine and serotonin transporters in patients with schizophrenia: an imaging study with [(123)I]beta-CIT.

  2000cited by this paper
• A voxel-by-voxel analysis of [18F]setoperone PET data shows no substantial serotonin 5-HT2A receptor changes in schizophrenia

  2000cited by this paper
• Prolactin hyperresponsiveness to D-fenfluramine in drug-free schizophrenic patients: a placebo-controlled study.

  1999cited by this paper
• No change in the density of the serotonin1A receptor, the serotonin4 receptor or the serotonin transporter in the dorsolateral prefrontal cortex from subjects with schizophrenia.

  1999cited by this paper
• A review of central 5-HT receptors and their function.

  1999cited by this paper
• Serotonin 5-HT2 receptors in schizophrenia: a PET study using [18F]setoperone in neuroleptic-naive patients and normal subjects.

  1999cited by this paper
• PET imaging of serotonin 1A receptor binding in depression.

  1999cited by this paper
• No Correlation between A(–1438)G Polymorphism in 5-HT2A Receptor Gene Promoter and the Density of Frontal Cortical 5-HT2A Receptors in Schizophrenia

  1999cited by this paper
• Abnormal persistence of cerebellar serotonin-1A receptors in schizophrenia suggests failure to regress in neonates

  1998cited by this paper
• Increased anxiety of mice lacking the serotonin1A receptor.

  1998cited by this paper
• Tryptophan Depletion During Continuous CSF Sampling in Healthy Human Subjects

  1998cited by this paper
• Prolactin response to D-fenfluramine challenge test as a predictor of treatment response to haloperidol in acute schizophrenia.

  1998cited by this paper
• No serotonin 5-HT2A receptor density abnormality in the cortex of schizophrenic patients studied with PET.

  1998cited by this paper
• The spectrum of behaviors influenced by serotonin.

  1998cited by this paper
• Serotonin receptor 1A knockout: an animal model of anxiety-related disorder.

  1998cited by this paper
• 5-HT1A receptor binding sites in post-mortem brain samples from depressed suicides and controls.

  1997cited by this paper
• [3H]WAY-100635 for 5-HT1A receptor autoradiography in human brain: a comparison with [3H]8-OH-DPAT and demonstration of increased binding in the frontal cortex in schizophrenia.

  1997cited by this paper

• Multimodal neuroimaging reveals brain neurochemical disturbances associated with superoxide dismutase in first-episode drug-naïve schizophrenia

  2026cites this paper
• Parsing the neuroanatomy of schizophrenia to enhance the translational validity of preclinical models - a multidisciplinary perspective.

  2026cites this paper
• Guided by Expectations: Overweighted Semantic Priors in Schizotypy and their Links to Glutamate.

  2025cites this paper
• Role of Serotonin in the Neurobiology of Schizophrenia and Association With Negative Symptoms.

  2025cites this paper
• Network-based Molecular Constraints on in vivo Synaptic Density Alterations in Schizophrenia

  2025cites this paper
• Transcriptional and neurochemical signatures of cerebral blood flow alterations in schizophrenia and individuals at clinical high-risk for psychosis.

  2025influential citation
• New Agents in the Treatment of Psychiatric Disorders: What Innovations and in What Areas of Psychopathology?

  2025cites this paper
• Impact of selected second and third generation antipsychotics on cognitive dysfunction in schizophrenia-spectrum disorders. Systematic review and network meta-analysis.

  2025cites this paper
• Epigenetic Control in Schizophrenia.

  2025cites this paper
• IUPHAR REVIEW: Moving beyond dopamine-based therapeutic strategies for schizophrenia.

  2025cites this paper
• An umbrella review of neuroimaging studies and conceptual framework linking pathophysiology and psychopathology in schizophrenia

  2025cites this paper
• Digital phenotyping evidence for the reduced positivity offset as a mechanism underlying anhedonia among individuals at clinical high-risk for psychosis.

  2025cites this paper
• Chronic stress-induced neuroplasticity in the prefrontal cortex: Structural, functional, and molecular mechanisms from development to aging.

  2025cites this paper
• Cortical 5-HT2A receptors in depression and suicide: a systematic review and meta-analysis of in vivo and post-mortem imaging studies

  2025cites this paper
• Advancements in Managing Schizophrenia through Classical Approaches, Mechanisms, and Deep Brain Stimulation.

  2025cites this paper
• Transcriptomic and Neurotransmitter Insights Into Gray Matter Volume Changes From 1 Hz rTMS in Treating Schizophrenia With Auditory Verbal Hallucinations

  2025cites this paper
• Role of PI3K/Akt axis in cognitive impact of lumateperone in schizophrenia rat model induced by ketamine.

  2025cites this paper
• α7 nicotinic acetylcholine receptor, activated glia, and cognitive impairment in schizophrenia: a dual-tracer PET study

  2025cites this paper
• Unravelling the genetic and molecular basis of low-frequency rTMS induced changes in functional connectivity density in schizophrenia patients with auditory verbal hallucinations

  2025cites this paper
• Serotonin (5‐Hydroxytryptamine): Metabolism, Signaling, Biological Functions, Diseases, and Emerging Therapeutic Opportunities

  2025cites this paper
• Neuroanatomical Correlates of Negative Symptoms in Schizophrenia

  2025cites this paper
• Clinical and genetic associations of depressive symptoms in paranoid schizophrenia

  2025cites this paper
• Corticosterone modulates dopamine and serotonin1A receptor mediated regulation of prepulse inhibition and startle in male rats.

  2025cites this paper
• Oxidative Stress-Mediated Neuroinflammation in the Pathophysiology of Schizophrenia

  2025influential citation
• Characterization of the white matter networks in schizophrenia patients with metabolic syndrome undergoing risperidone or clozapine treatment

  2025cites this paper
• Overview of Novel Antipsychotic Drugs: State of the Art, New Mechanisms, and Clinical Aspects of Promising Compounds

  2025cites this paper
• Molecular Evidence Underlying the Dopamine Hypothesis of Schizophrenia

  2025cites this paper
• Advances in the Treatment of Cognitive Impairment in Schizophrenia: Targeting NMDA Receptor Pathways

  2024cites this paper
• The Serotonin Hypothesis: An Umbrella Review of Depression Evidence

  2024cites this paper
• A connectome-wide association study of altered functional connectivity in schizophrenia based on resting-state fMRI.

  2024cites this paper
• Activity of prefrontal cortex serotonin 2A receptor expressing neurons is necessary for the head-twitch response of mice to psychedelic drug DOI in a sex-dependent manner

  2024cites this paper
• Transcriptional and neurochemical signatures of cerebral blood flow alterations in schizophrenia and the clinical high-risk state for psychosis

  2024cites this paper
• Longitudinal study of insomnia, suicidal ideation, and psychopathology in schizophrenia.

  2024cites this paper
• Mit PET-Bildgebung psychischen Erkrankungen auf der Spur

  2024cites this paper
• Beyond dopamine: Novel strategies for schizophrenia treatment

  2024cites this paper
• Assessment of Innovative Pharmacological Targets in Schizophrenia

  2024cites this paper
• Substances led to Psychosis: A Systematic Review

  2024cites this paper
• Treatment-Resistant Schizophrenia, Clozapine Resistance, Genetic Associations, and Implications for Precision Psychiatry: A Scoping Review

  2023cites this paper
• Neurotransmission-related gene expression in the frontal pole is altered in subjects with bipolar disorder and schizophrenia

  2023cites this paper
• The role of sleep deprivation in physiological system dysfunctions

  2023cites this paper
• MicroRNA Schizophrenia: Etiology, Biomarkers and Therapeutic Targets.

  2023cites this paper
• Sleep Problems, Suicidal Ideation, and Psychopathology in First-Episode Psychosis.

  2023cites this paper
• Meta-analysis of insomnia, suicide, and psychopathology in schizophrenia

  2023cites this paper
• Potential plasma biomarker panels identification for the diagnosis of first-episode schizophrenia and monitoring antipsychotic monotherapy with the use of metabolomics analyses.

  2023cites this paper
• Captive ERVWE1 triggers impairment of 5-HT neuronal plasticity in the first-episode schizophrenia by post-transcriptional activation of HTR1B in ALKBH5-m6A dependent epigenetic mechanisms

  2023cites this paper
• Associating Multimodal Neuroimaging Abnormalities With the Transcriptome and Neurotransmitter Signatures in Schizophrenia.

  2023cites this paper
• The phenomenon of therapeutic resistance in the treatment of schizophrenia: the possibilities of modern diagnostics and methods of anti-resistant effects

  2023cites this paper
• Intestinal Enteroendocrine Cells: Present and Future Druggable Targets

  2023cites this paper
• Atypical antipsychotics attenuate MK801-induced social withdrawal and hyperlocomotion in the RHA rat model of schizophrenia-relevant features

  2023cites this paper
• Tryptophan challenge in individuals with schizophrenia and healthy controls: acute effects on circulating kynurenine and kynurenic acid, cognition and cerebral blood flow

  2023cites this paper
• Abnormal interhemispheric functional cooperation in schizophrenia follows the neurotransmitter profiles

  2023cites this paper
• Opţiuni terapeutice în schizofrenia ultrarezistentă. Intervenţii farmacologice (I)

  2023cites this paper
• Altered medial prefrontal cortex and dorsal raphé activity predict genotype and correlate with abnormal learning behavior in a mouse model of autism‐associated 2p16.3 deletion

  2022cites this paper
• Neurotransmission-Related Gene Expression in the Frontal Pole (Brodmann Area 10) is Altered in Subjects with Bipolar Disorder and Schizophrenia

  2022cites this paper
• Trace amine-associated receptor 1 (TAAR1) agonism as a new treatment strategy for schizophrenia and related disorders.

  2022cites this paper
• Cognitive impairment in psychiatric diseases: Biomarkers of diagnosis, treatment, and prevention

  2022influential citation
• the pathways underlying

  2022cites this paper
• Presynaptic 5-HT2A-mGlu2/3 Receptor–Receptor Crosstalk in the Prefrontal Cortex: Metamodulation of Glutamate Exocytosis

  2022cites this paper
• Brain instability in dynamic functional connectivity in schizophrenia

  2022cites this paper
• MOST INFORMATIVE EPIGENETIC MARKERS TO THE HUMAN PSYCHOEMOTIONAL STATE

  2022cites this paper
• Can epigenetics shine a light on the biological pathways underlying major mental disorders?

  2022cites this paper
• Increased blood-brain barrier permeability of the thalamus and the correlation with symptom severity and brain volume alterations in schizophrenia patients.

  2022cites this paper
• Prognostication of Functional Outcomes of Schizophrenia Using a Multigene Panel

  2022cites this paper
• Beyond monoamines: I. Novel targets and radiotracers for Positron emission tomography imaging in psychiatric disorders

  2022cites this paper
• Genetic mechanisms underlying gray matter volume changes in patients with drug-naive first-episode schizophrenia.

  2022cites this paper
• New Atypical Antipsychotics in the Treatment of Schizophrenia and Depression

  2022cites this paper
• Network Analysis of the Structure of the Core Symptoms and Clinical Correlates in Comorbid Schizophrenia and Gambling Disorder

  2022cites this paper
• Characterizing thalamocortical (dys)connectivity following d-amphetamine, LSD, and MDMA administration.

  2022cites this paper
• The prevalence and features of schizophrenia among individuals with gambling disorder.

  2021cites this paper
• Acute sleep deprivation upregulates serotonin 2A receptors in the frontal cortex of mice via the immediate early gene Egr3

  2021cites this paper
• New and emerging treatments for schizophrenia: a narrative review of their pharmacology, efficacy and side-effect profile relative to established antipsychotics

  2021cites this paper
• Towards in vivo imaging of functionally active 5-HT1A receptors in schizophrenia: concepts and challenges

  2021cites this paper
• [Autoinmune psychosis].

  2021cites this paper
• Therapeutic Potential of TAAR1 Agonists in Schizophrenia: Evidence from Preclinical Models and Clinical Studies

  2021cites this paper
• Serotonin 2A receptors and cannabinoids.

  2021cites this paper
• The Roles of Serotonin in Neuropsychiatric Disorders

  2021cites this paper
• Aripiprazole Lauroxil, a Novel Injectable Long-Acting Antipsychotic Treatment for Adults with Schizophrenia: A Comprehensive Review

  2021cites this paper
• Lumateperone tosylate, A Selective and Concurrent Modulator of Serotonin, Dopamine, and Glutamate, in the Treatment of Schizophrenia.

  2021cites this paper
• Paliperidone Reversion of Maternal Immune Activation-Induced Changes on Brain Serotonin and Kynurenine Pathways

  2021cites this paper
• Mechanisms of Synaptic Transmission Dysregulation in the Prefrontal Cortex: Pathophysiological Implications

  2021cites this paper
• Opposite alterations of 5HT2A receptor brain density in subjects with schizophrenia: relevance of radiotracers pharmacological profile

  2021cites this paper
• Shedding light on the role of CX3CR1 in the pathogenesis of schizophrenia

  2021cites this paper
• The Role of G Protein-Coupled Receptors (GPCRs) and Calcium Signaling in Schizophrenia. Focus on GPCRs Activated by Neurotransmitters and Chemokines

  2021cites this paper
• Estrogen Pendulum in Schizophrenia and Alzheimer's Disease: Review of Therapeutic Benefits and Outstanding Questions.

  2021cites this paper
• Long-term effects of young-adult methamphetamine on dorsal raphe serotonin systems in mice: role of brain-derived neurotrophic factor.

  2021cites this paper
• [Prognosis of the functional outcome of schizophrenia using a multigene panel].

  2021cites this paper
• Genetic Polymorphisms of 5-HT Receptors and Antipsychotic-Induced Metabolic Dysfunction in Patients with Schizophrenia

  2021cites this paper
• INCREASED AMYGDALA AND DECREASED HIPPOCAMPUS VOLUME AFTER SCHEDULE-INDUCED POLYDIPSIA IN HIGH DRINKER COMPULSIVE RATS.

  2020cites this paper
• The role of the gut microbiome in the development of schizophrenia.

  2020cites this paper
• In vitro characterization of the serotonin biosynthesis pathway by CEST MRI

  2020cites this paper
• Dopamine and Response to Antipsychotic Medication

  2020cites this paper
• Frontal GABA in schizophrenia: A meta-analysis of 1H-MRS studies

  2020cites this paper
• Schizophrenia and drug addiction comorbidity: recent advances in our understanding of behavioural susceptibility and neural mechanisms

  2020cites this paper
• The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research

  2020cites this paper
• 5-HT2A receptor-mediated Gαq/11 activation in psychiatric disorders: A postmortem study

  2020cites this paper
• Genetic variability of serotonin pathway associated with schizophrenia onset, progression, and treatment

  2020cites this paper
• Schizophrenia-An Overview.

  2020cites this paper
• Serotonin and schizophrenia

  2020cites this paper
• Functional polymorphisms and transcriptional analysis in the 5′ region of the human serotonin receptor 1B gene (HTR1B) and their associations with psychiatric disorders

  2020cites this paper
• Antipsychotics: Mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology

  2020cites this paper